MIRA — MIRA Pharmaceuticals, Inc. Common Stock
NASDAQ · Healthcare · Drug Manufacturers - General
$0.85
-$0.01 (-0.70%)
MIRA Pharmaceuticals, Inc. Common Stock (MIRA) is a drug manufacturers - general company listed on NASDAQ. It is led by Erez Aminov, based in 1200 Brickell Avenue, Miami, FL, United States, 33131. MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
Net income was -$1.1M. MIRA currently screens at market cap $41.1M.
Use this MIRA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MIRA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MIRA SEC filings page. Lician reads the product cache first so this HTML stays unique to MIRA Pharmaceuticals, Inc. Common Stock even when a live quote feed is slow.
About MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
MIRA Key Statistics
Market Cap
$41.11M
Volume
34,680
Previous Close
$0.79
Day Range
$0.77 – $0.81
P/B Ratio
4.40
EPS
-$0.51
Revenue
$0.00
Net Income
-$7.85M
Gross Profit
$0.00
Free Cash Flow
$0.00
MIRA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$7.85M | -$11.98M | -$7.06M |
| EPS (Diluted) | -$0.51 | -$0.85 | -$0.40 |
Total Assets
$2.92M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$2.83M
Operating Cash Flow
-$5.56M
Free Cash Flow
$0.00
MIRA Pharmaceuticals, Inc. Common Stock Company Information
- CEO & Chairman
- Erez Aminov
- Headquarters
- 1200 Brickell Avenue, Miami, FL, United States, 33131
- Website
- mirapharmaceuticals.com
- Phone
- 786 432 9792
- IPO / Founded
- 2023-08-03
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General